Nefecon Shows IgAN Benefits Regardless of Baseline eGFR

Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jun 6, 2025-

Nefecon Shows IgAN Benefits Regardless of Baseline eGFR

A subanalysis of the NeflgArd study shows benefits in eGFR and urine protein-creatinine ratio at baseline and across timepoints, regardless of baseline kidney function.

ERA 25: Data Underscore Iptacopan’s Effect on Proteinuria and Complement Activation in IgAN

New data from a phase 2 and an OLE trial provide additional insight into the effects of iptacopan in IgA nephropathy.